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Treatment of Pediatric Graves Disease:  
results of a multicenter survey in Portugal 
Background and objective 
Pediatric Graves Disease (GD) is a rare disease and there is currently no evidence-based strategy for its management. Therapy choice is determined by 
individual consideration of the risks and benefits of the three treatment modalities and varies considerably within and between countries, depending on local 
traditions and resources and on the different clinical conditions of the patients. 
In 2011, American Thyroid Association (ATA) and the American Association of Clinical Endocrinologists (AACE) published Guidelines on GD, changing 
disease`s evaluation. Nevertheless, GD treatment is still a matter of controversy.  
The main objective was to know the characteristics of the pediatric Portuguese GD population, how the different therapies were used and their results.  
Printed by 
SPEDP conducted the first nationwide questionnaire survey among all the Endocrinologists and Pediatricians in the Portuguese Public 
Health System Hospitals about pediatric GD treatment. A questionnaire (Fig. 1) was designed and distributed to all hospitals with pediatric 
endocrinology, in order to include all GD patients under 18 years at diagnosis and with a minimum of 6 months follow-up. A retrospective 
assessment of patient`s medical records was performed from May to  August 2013. 
For the statistical analysis we used Excell® and SPSS®.  We used Kruskal-Wallis Test and Spearman’s correlation and considered a level 
of significance of 5%. 
Portuguese Endocrinology and Diabetes Pediatric Society (SPEDP): Marques,O; Oliveira, MJ; Antunes, A; Espada, F; 
Guimarães, J. and Portuguese Multicentre Group: Mirante A, Monteiro A; Vasconcelos C, Meireles C; Brandão C; Galo E; 
Fernandes I; Anselmo J; Lopes L; Sampaio L; Fonseca M; Almeida M; Ferreira M; Anselmo M; Campos R A; Bernardo T; 
Borges T; Pratas S; Sousa S; Silva T; Leite V 
• 87 hospitals contacted, 67 responders 
• 25 hospitals reported patients  
• Pediatric clinic – 56%; Endocrinology clinic – 44%  
• 152 patients were identified, 76% were females 
• Mean age at diagnosis: 11,3 ±3,4  years [3,3-18,3] 
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No remission p 
Number of patients (%) 39 (42,4%) 26 (28,3%) 27 (29,3%) NS 
Age at diagnosis (years) 10.57+3.36 12.02+3.32 11.46+3.60 NS 
Type ATD  (PTU/TMZ) 23/16 7/19* 9/18* 0.02* 
ATD duration (months) 35.59+22.24 26.85+14.89 41.67+47.61 NS 
MTZ dose (mg/Kg) 0.36+0.14 0.42+0.19 0.40+0.18 NS 
PTU dose (mg/Kg) 3.96+2.07 2.33+2.46 5.71+3.16** 0.024** 
Combination therapy 
(ATD+LT4) (N/%) 
20 (51,3%) 17 (65,4%) 10 (37,0%) NS 
*p<0.05 vs remission, no relapse; **p<0.05 vs remission and relapse 
Initial and final TRABs and remission status (N=92)  
A statistically significant positive association between final, (but not inicial (p=0.272)) TRABs and remission/relapse category was found. Patients without 









































































This first multicenter portuguese survey is representative of the national pediatric GD population as it included 77% of all hospitals in our country. ATD therapy 
was the first choice for all patients, MTZ being preferred. Only minor adverse effects of the drugs were found. Despite a long treatment duration, only 25% 
patients achieved long term remission. Definitive therapy was a second choice in few patients (22.4%) and more frequent in recent years. Few significant 
predictive factors of remission were found between groups that finished first course of ATD, namely lower final TRABs and the use of MTZ instead of PTU.  
Our population results are conform with literature and reflect a tendency to change GD therapy, introducing definite therapy sooner in the course of treatment. 














































































































































Figure 2 – Age at dianosis 
Figure 3 – Duration of firts course of ATD (months) 
Table 1 – Initial treatment with ATD and adverse effects 
Table 2 –  Caracterization of patients that stopped ATD 
Figure 4 – Comparison of TRABs before and after treatment 
(increased number of times) 
Figure 5 – Treatment evolution 
Figure 6 – Duration of treatment  in patients  ongoing first ATD course (months) 
Figure 7 – Initial and final TRABs (increased number of times) and remission/relapse status 
Figure 1 – Questionnaire 
Patients ongoing first course ATD (N=60) 
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